Trial Profile
A Phase 3, Multi-Center, Open-Label, Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Two 6-Month Leuprolide Formulations, in Subjects With Prostatic Adenocarcinoma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Abbott Laboratories; TAP Pharmaceuticals
- 13 May 2010 Additional trial identifier 1B-08-2 identified as reported by University of Southern California Norris Comprehensive Cancer Center record.
- 13 May 2010 New source identified and integrated (University of Southern California Norris Comprehensive Cancer Center record no. 1B-08-2).
- 11 Mar 2010 Based on the results of this study, the US FDA has accepted for review a supplemental New Drug Application of a 6-month 45mg formulation of leuprorelin for the treatment of advanced prostate cancer, according to an Abbott Laboratories media release.